Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients

British Journal of Clinical Pharmacology

Volumn 64, Issue 6, 2007, Pages 758-771

  Pescovitz, Mark D ^a   Vincenti, Flavio ^b   Hart, Marquis ^c   Melton, Larry ^d   Whelchel, John ^e   Mulgaonkar, Shamkant ^f   McKay, Diane ^g   Leung, Mimi ^h   Calleja, Elizabeth ^h   Bouw, M René ^g  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e PIEDMONT HOSPITAL   (United States)

^f SAINT BARNABAS MEDICAL CENTER   (United States)

^g ROCHE PRODUCTS LTD   (United Kingdom)

^h HOFFMANN LA ROCHE INC   (United States)

Author keywords

Ciclosporin; Mycophenolate mofetil; Pharmacokinetics; Renal transplant; Sirolimus

Indexed keywords

CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; DACLIZUMAB; DRUG METABOLITE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

ACNE; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; DYSURIA; EDEMA; ERYTHROPENIA; FATIGUE; FEMALE; FEVER; GRAFT RECIPIENT; GRAFT REJECTION; HEADACHE; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPERVOLEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INSOMNIA; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; KIDNEY TUBULE NECROSIS; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; NEPHRITIS; NEPHROTOXICITY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SORE THROAT; THROMBOCYTOPENIA; TREMOR; VERRUCA VULGARIS; VOMITING; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

ADULT; AGED; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; LEUKOPENIA; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; SIROLIMUS;

EID: 36849071973     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02934.x     Document Type: Article

References (37)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004 4 : 378 83.
2. Kaufman DB, Shapiro R, Lucey MR, Cherikh WS, Bustami RT, Dyke D. Immunosuppression: practice and trends. Am J Transplant 2004 4 (Suppl 9 38 53.
3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003 349 : 2326 33.
4. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs. long-term consequences and challenges for the future. Am J Kidney Dis 2000 35 : 333 46.
5. Kasiske BL, Tortorice KL, Heim-Duthoy KL, Awni WM, Rao KV. The adverse impact of cyclosporine on serum lipids in renal transplant recipients. Am J Kidney Dis 1991 17 : 700 7.
6. Schorn TF, Kliem V, Bojanovski M, Bojanovski D, Repp H, Bunzendahl H, Frei U. Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients. Transpl Int 1991 4 : 92 5.
7. Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B, Eigler FW, Heemann U, Pichlmayr R, Behrend M, Vanrenterghem Y, Donck J, van Hooff J, Christiaans M, Morales JM, Andres A, Johnson RW, Short C, Buchholz B, Rehmert N, Land W, Schleibner S, Forsythe JL, Talbot D, Pohanka E. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997 64 : 436 43.
8. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998 31 : 335 40.
9. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, Brattstrom C, Charpentier B. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999 67 : 1036 42.
10. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000 356 : 194 202.
11. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001 71 : 271 80.
12. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 1999 68 : 1526 32.
13. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook DJ, Novick AC. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus vs. cyclosporine. Transplantation 2002 74 : 1070 6.
14. Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattstrom C, Lebranchu Y, Vialtel P. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000 69 : 1252 60.
15. Dunn J, Vathsala A, Golden D, Kerman R, Lawen J, Van Buren CT, Lewis R, Kahan BD. Impact of race on the outcome of renal transplantation under cyclosporine-prednisone. Transplant Proc 1989 21 : 3946 8.
16. Opelz G, Pfarr E, Engelmann A, Keppel E. Kidney graft survival rates in black cyclosporine-treated recipients. Collaborative Transplant Study. Transplant Proc 1989 21 : 3918 20.
17. Katznelson S, Gjertson DW, Cecka JM. The effect of race and ethnicity on kidney allograft outcome. Clin Transpl 1995 : 379 94.
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 : 31 41.
19. Guesry P, Kaufman L, Orloff S, Nelson JA, Swann S, Holliday M. Measurement of glomerular filtration rate by fluorescent excitation of non-radioactive meglumine iothalamate. Clin Nephrol 1975 3 : 134 8.
20. Buchler M, Lebranchu Y, Beneton M, Le Meur Y, Heng AE, Westeel PF, le Guellec C, Libert F, Hary L, Marquet P, Paintaud G. Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. Clin Pharmacol Ther 2005 78 : 34 42.
21. El Haggan W, Ficheux M, Debruyne D, Rognant N, Lobbedez T, Allard C, Coquerel A, Ryckelynck JP, Hurault de Ligny B. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus vs. cyclosporine. Transplant Proc 2005 37 : 864 6.
22. Cattaneo D, Merlini S, Zenoni S, Baldelli S, Gotti E, Remuzzi G, Perico N. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant 2005 5 : 2937 44.
23. Gregoor PJ, de Sevaux RG, Hene RJ, Hesse CJ, Hilbrands LB, Vos P, van Gelder T, Hoitsma AJ, Weimar W. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999 68 : 1603 6.
24. Smak Gregoor PJ, van Gelder T, Hesse CJ, van der Mast BJ, van Besouw NM, Weimar W. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant 1999 14 : 706 8.
25. Pou L, Brunet M, Cantarell C, Vidal E, Oppenheimer F, Monforte V, Vilardell J, Roman A, Martorell J, Capdevila L. Mycophenolic acid plasma concentrations: influence of comedication. Ther Drug Monit 2001 23 : 35 8.
26. Shaw LM, Korecka M, DeNofrio D, Brayman KL. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem 2001 34 : 17 22.
27. Aw MM, Brown NW, Itsuka T, Gonde CE, Adams JE, Heaton ND, Tredger JM, Mieli-Vergani G, Dhawan A. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. Liver Transpl 2003 9 : 383 8.
28. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000 118 : 422 30.
29. Morrow CS, Smitherman PK, Townsend AJ. Role of multidrug-resistance protein 2 in glutathione S-transferase P1-1-mediated resistance to 4-nitroquinoline 1-oxide toxicities in HepG2 cells. Mol Carcinog 2000 29 : 170 8.
30. Bramow S, Ott P, Thomsen Nielsen F, Bangert K, Tygstrup N, Dalhoff K. Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin). Pharmacol Toxicol 2001 89 : 133 9.
31. Kobayashi M, Saitoh H, Tadano K, Takahashi Y, Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 2004 309 : 1029 35.
32. van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Toenschoff B, Mamelok R. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Is Ther Drug Monit 2006 28 : 145 54.
33. Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998 63 : 48 53.
34. Brattstrom C, Wilczek H, Tyden G, Bottiger Y, Sawe J, Groth CG. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998 65 : 1272 4.
35. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients. risk factors, incidence, progression, and management. Transplantation 2000 69 : 2085 90.
36. Valente JF, Hricik D, Weigel K, Seaman D, Knauss T, Siegel CT, Bodziak K, Schulak JA. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003 3 : 1128 34.
37. Dean PG, Lund WJ, Larson TS, Prieto M, Nyberg SL, Ishitani MB, Kremers WK, Stegall MD. Wound-healing complications after kidney transplantation. a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004 77 : 1555 61.